Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy

INTRODUCTION AND AIMS Injecting opioid users are at elevated risk of death. Although liver disease (especially hepatitis C) is common, its impact on mortality is low in active injectors. Because opioid substitution therapy (OST) reduces the risk of death from directly drug related causes, we hypothesised that the proportion of liver-related deaths would increase in subjects receiving OST. We investigated liver-related mortality in a cohort of injecting opioid users attending a needle exchange program (NEP) in a Swedish city in relation to OST exposure. DESIGN AND METHODS Participants enrolled in the NEP between 1987 and 2011 with available national identity numbers, and registered use of opioids, were included. Linkage based on national identity numbers was performed with national registers for death, emigration and prescription of OST. Participants were categorised as non-OST recipients until the registered date of first OST prescription, and hence as OST recipients. Hazard ratios were calculated by Cox regression for overall and liver-related mortality in relation to OST, with OST as a time-dependent variable. RESULTS Among 4494 NEP participants, 1488 opioid users were identified; 711/1488 had been prescribed OST. During a follow-up period of 15 546 person-years 368 deaths occurred. Sixteen deaths were caused by liver disease; 10 of these occurred in OST recipients. The risk of liver-related death was significantly increased in OST receiving participants (hazard ratio 3.08, 95% confidence interval [1.09, 8.68], P = 0.03). CONCLUSIONS Liver related mortality among opioid users was significantly elevated in OST recipients, showing the long-term importance of chronic liver disease in this population. [Jerkeman A, Håkansson A, Rylance R, Wagner P, Alanko Blomé M, Björkman P. Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy. Drug Alcohol Rev 2017;36:424-431].

[1]  A. Widell,et al.  Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy—Factors associated with advanced fibrosis , 2014, Scandinavian journal of infectious diseases.

[2]  H. Wand,et al.  Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011 , 2014, Journal of viral hepatitis.

[3]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[4]  A. Pharris,et al.  Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.

[5]  D. Randall,et al.  The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. , 2013, Drug and alcohol dependence.

[6]  C. Sabin,et al.  Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. , 2013, Gastroenterology.

[7]  D. D. Des Jarlais,et al.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Bucello,et al.  Mortality among people who inject drugs: a systematic review and meta-analysis. , 2013, Bulletin of the World Health Organization.

[9]  K. Kielland,et al.  All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.

[10]  A. Muñoz,et al.  Unhealthy Alcohol Use, HIV Infection and Risk of Liver Fibrosis in Drug Users with Hepatitis C , 2012, PloS one.

[11]  C. Lewden,et al.  All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. , 2012, Journal of hepatology.

[12]  C. Mcgowan,et al.  Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[13]  A. Widell,et al.  The risk of cancer among persons with a history of injecting drug use in Sweden – a cohort study based on participants in a needle exchange program , 2012, Acta oncologica.

[14]  D. Randall,et al.  The increasing mortality burden of liver disease among opioid-dependent people: cohort study. , 2011, Addiction.

[15]  A. Widell,et al.  Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program , 2011, Journal of viral hepatitis.

[16]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[17]  L. Degenhardt,et al.  Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. , 2011, Addiction.

[18]  I. Thiblin,et al.  Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity? , 2010, Addiction.

[19]  M. Stenbacka,et al.  Mortality and cause of death among 1705 illicit drug users: a 37 year follow up. , 2009, Drug and alcohol review.

[20]  W. Hall,et al.  Mortality among amphetamine users: a systematic review of cohort studies. , 2009, Drug and alcohol dependence.

[21]  J. Raffa,et al.  Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.

[22]  L. Seeff.  The history of the “natural history” of hepatitis C (1968–2009) , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[23]  A. Kamarulzaman.  Global Epidemiology of Injecting Drug Use and HIV Among People Who Inject Drugs: A Systematic Review , 2008 .

[24]  D. D. Des Jarlais,et al.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. , 2008, American journal of epidemiology.

[25]  G. Dore,et al.  Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression , 2008, Hepatology.

[26]  M. Berglund,et al.  Factors associated with history of non-fatal overdose among opioid users in the Swedish criminal justice system. , 2008, Drug and alcohol dependence.

[27]  Jason M. White,et al.  Exposure to opioid maintenance treatment reduces long-term mortality. , 2008, Addiction.

[28]  D. Vlahov,et al.  Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.

[29]  J. Whitfield,et al.  Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. , 2007, Drug and alcohol review.

[30]  I. Thiblin,et al.  Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. , 2007, Addiction.

[31]  A. Helander,et al.  Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. , 2007, Drug and alcohol review.

[32]  C. Rück,et al.  A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. , 2007, The American journal of psychiatry.

[33]  Johan Duflou,et al.  Systemic disease among cases of fatal opioid toxicity. , 2006, Addiction.

[34]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[35]  S. Bird,et al.  Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  C. Holman,et al.  Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. , 2004, Addiction.

[37]  J. Pawlotsky,et al.  Impact of smoking on histological liver lesions in chronic hepatitis C , 2003, Gut.

[38]  R. Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2003, The Cochrane database of systematic reviews.

[39]  R P Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[40]  M. Sullivan,et al.  Current perspectives on smoking cessation among substance abusers , 2002, Current psychiatry reports.

[41]  M. Srisurapanont,et al.  Treatment for amphetamine dependence and abuse. , 2014, The Cochrane database of systematic reviews.

[42]  A. Mohsen,et al.  The epidemiology of hepatitis C in a UK health regional population of 5.12 million , 2001, Gut.

[43]  A. Widell,et al.  Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. , 2000, Scandinavian journal of infectious diseases.

[44]  G. Ottomanelli.  Methadone patients and alcohol abuse. , 1999, Journal of substance abuse treatment.

[45]  J. Rajs,et al.  Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981–1992 , 1997, Acta psychiatrica Scandinavica.

[46]  L. Öhlund,et al.  Mortality in heroin addiction: impact of methadone treatment , 1990, Acta psychiatrica Scandinavica.